Alzamend Neuro Files 8-K for Financial Statements

TL;DR

Alzamend Neuro filed an 8-K for exhibits, no new info.

AI Summary

Alzamend Neuro, Inc. filed an 8-K on May 13, 2024, to report financial statements and exhibits. The filing does not contain specific financial figures or details about new developments, but rather serves as a formal notification of submitted documents.

Why It Matters

This filing indicates that Alzamend Neuro has submitted required financial documentation to the SEC, which is a standard procedural step for public companies.

Risk Assessment

Risk Level: low — This filing is a routine procedural update and does not contain new material information that would significantly impact the company's risk profile.

Key Players & Entities

• Alzamend Neuro, Inc. (company) — Registrant
• May 13, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of incorporation
• 001-40483 (filing_id) — SEC File Number
• 81-1822909 (tax_id) — I.R.S. Employer Identification No.
• 3480 Peachtree Road NE , Second Floor , Suite 103 , Atlanta , GA 30326 (address) — Address of principal executive offices
• (844) 722-6333 (phone_number) — Registrant's telephone number

FAQ

Key Financial Figures

• $0.0001 — nge on which registered Common Stock, $0.0001 par value ALZN The Nasdaq Capital M
• $6,000,000 — ck, for a total purchase price of up to $6,000,000.00, pursuant to the Securities Purchase

Filing Documents

• o5132458k.htm (8-K) — 29KB
• 0001214659-24-008914.txt ( ) — 202KB
• alzn-20240513.xsd (EX-101.SCH) — 3KB
• alzn-20240513_lab.xml (EX-101.LAB) — 33KB
• alzn-20240513_pre.xml (EX-101.PRE) — 22KB
• o5132458k_htm.xml (XML) — 4KB

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. Alzamend Neuro, Inc., a Delaware corporation (the " Company ") held its held its annual meeting of stockholders (the " Annual Meeting ") on April 30, 2024, which Annual Meeting was adjourned (the " Adjourned Meeting ") to allow additional time for voting on Proposal 3 in the Company's proxy materials. Proposal 3 sought to approve, for purposes of complying with Listing Rule 5635 of The Nasdaq Stock Market, LLC, the issuance by the Company of additional shares of the Company's common stock, par value $0.0001 per share (the " Common Stock " ) issuable upon the (i) conversion of up to 6,000 shares of Series B convertible preferred stock (the " Series B Preferred Stock ") and (ii) exercise of warrants to purchase up to 6,000,000 shares of Common Stock, for a total purchase price of up to $6,000,000.00, pursuant to the Securities Purchase Agreement dated January 31, 2024 with Ault Lending, LLC (the " Series B Transaction "). At the time of the Annual Meeting, there were insufficient votes to pass Proposal 3 to authorize the Series B Transaction. The Adjourned Annual Meeting reconvened at 12:00 p.m. Eastern Time on May 13, 2024. As of March 14, 2024, the record date for the Adjourned Annual Meeting, the Company had outstanding and entitled to vote (i) 6,849,407 shares of Common Stock and (ii) 1,220,000 shares of Series B Preferred Stock, which together constitute all of the outstanding voting capital stock of the Company. At the Adjourned Annual Meeting, the stockholders voted on Proposal 3, which is described in more detail in the Company's definitive proxy statement on Schedule 14A filed with the U.S. Securities and Exchange Commission on March 25, 2024 as thereafter supplemented. At the Adjourned Annual Meeting, stockholders approved Proposal 3. The tables below set forth the number of votes cast for and against or withheld, and the number of abstentions or broker non-votes, for Proposal 3 voted upon b

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 101 Pursuant to Rule 406 of Regulation S-T, the cover page is formatted in Inline XBRL (Inline eXtensible Business Reporting Language). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document and included in Exhibit 101). -2- SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ALZAMEND NEURO, INC. Dated: May 13, 2024 /s/ David J. Katzoff David J. Katzoff Chief Financial Officer -3-

View Full Filing

View this 8-K filing on SEC EDGAR